Juno Therapeutics has presented updated TRANSCEND NHL 001 trial data showing high durable response rates in patients with relapsed or refractory CD19+ aggressive non-hodgkin lymphoma at the 2017 Annual Meeting of the American Society for Clinical Oncology (ASCO).
Teva Pharmaceutical Industries has reported positive results from a Phase III HALO study for its migraine drug fremanezumab.
Biopharmaceutical firm Lysogene has completed enrollment of patients in its “Sanfilippo A Multi-national Observational Study” (SAMOS).
Neurocrine Biosciences said that the initial phase II Tourette syndrome T-Force GREEN study of INGREZZA (valbenazine), a small molecule VMAT2 inhibitor, did not meet its primary endpoint.
Inovio Pharmaceuticals' Pennvax-GP HIV vaccine has demonstrated nearly 100% immune response rates in a clinical study.
Inovio Pharmaceuticals has reported that its Pennvax-GP HIV vaccine combination has succeeded in an early stage clinical trial by evoking nearly 100% immune response rates in participants.
Shire’s swelling disorder treatment, lanadelumab, has met its primary endpoint and all secondary endpoints in a phase 3 study.
ImmunoGen has reported promising safety and efficacy data from monotherapy and combination trials with mirvetuximab soravtansine in patients with folate receptor alpha (FRα)-positive epithelial ovarian cancer (EOC).
Ardelyx reported positive, topline results from the T3MPO-1 trial, the first of two Phase 3 trials evaluating tenapanor for the treatment of patients with irritable bowel syndrome with constipation (IBS-C).
Eli Lilly's galcanezumab has met its primary endpoint in three phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) showing statistically significant reductions in the number of monthly migraine headache days against placebo at both studied doses.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.